| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |
ciprofloxacin is a strong inhibitor of CYP1A2. ciprofloxacin did not meet the criteria of being an inhibitor or inducer of CYP3A.
- Strong inhibitors: ≥ 5-fold increase in AUC or ≥ 80% decrease in clearance of in vivo CYP probe.
- Criteria not met: drugs evaluated in clinical PK interactions studies that do not meet the inclusion criteria (see Methods).
Footnotes and References
|a.||assessment based on product information accessed via the Therapeutic Goods Administration of Australia Product and Consumer Medicines Information website ( https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=PI&q=&r=https://www.ebs.tga.gov.au/ ).|
|b.||clinical PK interaction studies referred to in product information.|
|c.||likely to be a major inhibitor based on subjective evaluation (≥ 2-fold AUC increase or ≥ 50% decrease in clearance of in vivo CYP probe).|
|d.||likely to be a major inducer based on subjective evaluation (≥ 2-fold decrease in AUC or ≥ 50% increase in clearance of in vivo CYP probe).|
|1.||Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and cypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clinical Pharmacology & Therapeutics 2004; 76: 598-606.[PubMed]|
|2.||Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ. Fluvoxamine Drastically Increases Concentrations and Effects of Tizanidine: A Potentially Hazardous Interaction. Clinical Pharmacology & Therapeutics 2004; 75: 331-41.[PubMed]|
|3.||Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clinical Pharmacology & Therapeutics 1998; 64: 133-43.[PubMed]|
|4.||Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clinical Pharmacology & Therapeutics 1997; 62: 348-54.[PubMed]|
|5.||Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. Clinical Pharmacology & Therapeutics 1998; 64: 655-60.[PubMed]|
|6.||Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology & Therapeutics 1994; 55: 481-85.[PubMed]|
|7.||Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJJ, Klein CE, Rublein JC, Kashuba ADM. Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers. Journal of Acquired Immune Deficiency Syndromes 2006; 42: 52-60.[PubMed]|
|8.||Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir. Clinical Pharmacology & Therapeutics 2006; 79: 243-54.[PubMed]|
|9.||Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clinical Pharmacology & Therapeutics 1999; 66: 33-39.[PubMed]|
|10.||Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 27-37.[PubMed]|
|11.||Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clinical Pharmacology & Therapeutics 2006; 79: 362-70.[PubMed]|
|12.||Upton RA. Pharmacokinetic interactions between theophylline and other medication (Part I). Clinical Pharmacokinetics 1990; 20: 66-80.[PubMed]|
|13.||Apseloff G, Shepard DR, Chambers MA, Nawoot S, Mays DC, Gerber N. Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. Drug Metabolism and Disposition 1990; 18: 298-303.[PubMed]|
|14.||Katial RK, Stelzle RC, Bonner MW, Marino M, Cantilena LR, Smith LJ. A drug interaction between zafirlukast and theophylline. Archives of Internal Medicine 1998; 158: 1713-15.[PubMed]|
|15.||Hedaya MA, El-Afify DR, El-Maghraby GM. The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharmaceutics & Drug Disposition 2006; 27: 103-10.[PubMed]|
|16.||Wire MB, Shelton MJ, Studenberg S. Fosamprenavir - Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clinical Pharmacokinetics 2006; 45: 137-68.[PubMed]|
|17.||Schellens JHM, Vanderwart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. Journal of Pharmacology and Experimental Therapeutics 1989; 249: 638-45.[PubMed]|
|18.||Abernethy DR, Greenblatt DJ, Morse DS, Shader RI. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. British Journal of Clinical Pharmacology 1985; 19: 51-54.[PubMed]|
DisclaimerWARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.